Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hyperion Therapeutics, a specialty therapeutics company, has reported that HPN-100 has received orphan product designation from the FDA for maintenance treatment of patients with enzymes of the urea cycle.
Subscribe to our email newsletter
The company has recently announced results from its Phase II study and intends to initiate a Phase III clinical program in this indication in the second half of 2009.
HPN-100 is a pre-pro-drug of phenylacetic acid which is the active moiety of Buphenyl, reportedly the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle deficiencies including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100 is dosed orally in liquid form.
Donald Santel, CEO of Hyperion, said: “Receiving orphan drug designation for HPN-100 in the treatment of urea cycle disorders is an important milestone and provides meaningful benefits to the company as we work to complete clinical trials for this investigational compound.”